Decoding Recent Investments in Long Read Technologies

There has been a bit of interesting activity in long read sequencing technology investment and acquisition in the past few weeks. First came Amgen’s ~$66M (£50M) investment in Oxford Nanopore Technologies, then a couple of weeks later, Illumina announced their $1.2B acquisition of Pacific Biosciences. Work in long read technologies has been going on for many years, so is this a sudden rush... or the culmination of long-term planning?

5 Questions With: Robert Green, MD, MPH Professor of Medicine (Genetics), Harvard Medical School

Continuing Chrysalis' "5 Questions" series, we reached out to one of the preeminent experts on the clinical use of whole genome sequencing. Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School. Dr. Green sees patients and conducts empirical research on the medical, behavioral and economic outcomes associated with the implementation of genomic medicine.

Comment

The Art and Science of Technology/Market Fit

We’ve taken our years of experience and distilled them down into some practices to help companies, big and small, make decisions about how and when to bring the right technologies to the right market. Taking a rigorous approach to find the right fit for a technology is a very important first step towards achieving commercial success. 

Comment

Comment

In the Defense of Genome-Wide Association Studies

In the recent article by Visscher et al., “10 Years of GWAS Discovery: Biology, Function, and Translation,” the authors pose a daunting question: “Does the GWAS have a future?” And this has led me to ask a higher-level question of my own:

 “Why does GWAS need defending?" 

Comment

Comment

5 Questions With: Erica Ramos

As part of our blog, Chrysalis Biomedical Advisors will be sharing a series of “5 Questions With...”. These are brief interviews with thought leaders in the healthcare and biotechnology space. We hope you enjoy them. Interested in nominating an individual and / or posing questions? Please contact rob@chrysalisbiomed.com or comment.

Comment